Executive Vice President, Inceptua Early Access
CurrentI am responsible for Inceptua's Early Access business unit, supporting pharmaceutical and biotech companies in making their medicines available to patients in need before commercialization. We work with Top 10 Pharma companies, through to small, niche biotechs as their trusted partner to ensure rapid, compliant provision of unlicensed medicines.We support all forms of Early Access, Compassionate Use, Named Patient Supply, Expanded Access, managing all regulatory submissions, supply chain, physician interactions and data collection.We have a truly global reach, with programs operational in over 100 countries spanning all 6 continents. From ultra-rare disease, to blockbuster oncology assets, from straightforward supply chain to complex, cold chain <2hr delivery for emergency treatments, Inceptua Early Access can develop custom programs for any asset, ensuring physicians and patients get the opportunity to use a promising new medicine potentially years before it will be available commercially. I was part of the management team who set up Inceptua Early Access in 2017. Within 12 months of launch, we secured Inceptua as the 2nd-placed vendor in the sector, based on number of active programs.